# To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder

> **NCT01263548** · — · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 45 (actual)

## Conditions studied

- Attention Deficit/Hyperactivity Disorder
- Bipolar Disorder

## Interventions

- **DRUG:** lisdexamfetamine dimesylate

## Key facts

- **NCT ID:** NCT01263548
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2012-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263548, "To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01263548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*